A 6-year-old boy with evidence of a second relapse of a neuroblastoma stadium 4 (high-risk group, negative MYCN amplification, negative 1p deletion; initial diagnosis: October 2016, first relapse: August 2017, second relapse: March 2019) was referred to the department of Pediatric Oncology and Hematology for stem cell transplantation. This evidence concerns the gene MYCN and neuroblastoma.